RIGHTS TRANSFER AGREEMENTRights Transfer Agreement • March 22nd, 2012 • Durata Therapeutics, Inc. • New York
This Rights Transfer Agreement (“Agreement”) is entered into as of December 14, 2010 (the “Effective Date”) by and between Durata Therapeutics, Inc., a Delaware corporation (“Durata”), Vicuron Pharmaceuticals, Inc., a Delaware corporation (“Vicuron”), and RaQualia Pharma Inc., a Japanese Kabushiki Kaisha (“RaQualia”). Durata and RaQualia are referred to herein together as the “Parties” and individually as a “Party”.
DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • March 22nd, 2012 • Durata Therapeutics, Inc. • Delaware
The information contained in this document is the property of the company and should not be divulged to unauthorized persons.
DURATA THERAPEUTICS, INC. STOCK INCENTIVE PLAN FORM OF STOCK OPTION AGREEMENTStock Option Agreement • March 22nd, 2012 • Durata Therapeutics, Inc. • Delaware
THIS STOCK OPTION AGREEMENT (this “Option Agreement”) dated by and between Durata Therapeutics, Inc., a Delaware corporation (the “Corporation”), and (the “Participant”) evidences the stock option (the “Option”) granted by the Corporation to the Participant as to the number of shares of the Corporation’s Common Stock, par value $0.01 per share, first set forth below.
INVESTOR RIGHTS AGREEMENT By and Among DURATA THERAPEUTICS, INC. and THE HOLDERS OF PREFERRED SHARES THEREOFInvestor Rights Agreement • March 22nd, 2012 • Durata Therapeutics, Inc. • New York
THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”) is dated as of December 11, 2009, and is by and among (i) Durata Therapeutics, Inc., a Delaware corporation (the “Company”), and (ii) the holders of Preferred Shares of the Company listed from time to time on the attached Schedule A (each an “Investor” and collectively, with their successors, transferees and assigns, the “Investors”).
